AR070911A1 - Uso de antagonistas del receptor par2 activado con proteasa - Google Patents
Uso de antagonistas del receptor par2 activado con proteasaInfo
- Publication number
- AR070911A1 AR070911A1 ARP090100937A ARP090100937A AR070911A1 AR 070911 A1 AR070911 A1 AR 070911A1 AR P090100937 A ARP090100937 A AR P090100937A AR P090100937 A ARP090100937 A AR P090100937A AR 070911 A1 AR070911 A1 AR 070911A1
- Authority
- AR
- Argentina
- Prior art keywords
- pain
- par2
- antagonist
- fracture
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Uso de un antagonista del receptor 2 activado con proteasa (PAR2) para el tratamiento del dolor que incluye el dolor postoperatorio en una incision, el dolor neuropático, el dolor por fractura, el dolor por fractura osteoporotica, el dolor por cáncer de hueso o el dolor articular por gota; el dolor inflamatorio asociado con el síndrome de colon irritable; y la inflamacion relacionada con la artritis reumatoide o la osteoartritis, el antagonista de PAR2 es un anticuerpo anti-PAR2 humano o un fragmento de un anticuerpo que se une al antígeno. Reivindicacion 6: Uso de un antagonista del receptor 2 activado con proteasa (PAR2) segun las reivindicaciones 4 o 5, y uno o varios agentes terapéuticos adicionales seleccionados a partir de otro antagonista de PAR2, un inhibidor de citocina, un fármaco antiepiléptico, un inhibidor de NGF, una colchicina, un fármaco anti-inflamatorio no esteroideo (NSAID), un corticoesteroide y un inhibidor de TNF, en la preparacion de un medicamento para tratar, inhibir o aliviar el dolor asociado con la inflamacion, el dolor postoperatorio en una incision, la neuropatía, la fractura de huesos, la fractura osteoporotica, el cáncer de hueso o la gota.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3790808P | 2008-03-19 | 2008-03-19 | |
| US11915508P | 2008-12-02 | 2008-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070911A1 true AR070911A1 (es) | 2010-05-12 |
Family
ID=40718925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100937A AR070911A1 (es) | 2008-03-19 | 2009-03-16 | Uso de antagonistas del receptor par2 activado con proteasa |
Country Status (6)
| Country | Link |
|---|---|
| AR (1) | AR070911A1 (es) |
| CL (1) | CL2009000660A1 (es) |
| PE (1) | PE20091693A1 (es) |
| TW (1) | TW201002345A (es) |
| UY (1) | UY31723A (es) |
| WO (1) | WO2009117481A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214655B2 (en) * | 2001-05-21 | 2007-05-08 | Johnson & Johnson Consumer Companies, Inc. | Peptides and the use thereof in darkening the skin |
| US7888482B2 (en) | 2006-02-10 | 2011-02-15 | Amgen Inc. | Antibodies that bind PAR-2 |
| JO3246B1 (ar) | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| AU2012331140A1 (en) | 2011-11-04 | 2014-05-08 | Lipotec, S.A. | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions |
| AU2014326596B2 (en) | 2013-09-25 | 2018-12-13 | Vertex Pharmaceuticals Incorporated | Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway |
| US20160000791A1 (en) | 2014-07-07 | 2016-01-07 | Mayo Foundation For Medical Education And Research | Par1 modulation to alter myelination |
| JP2019516734A (ja) * | 2016-05-20 | 2019-06-20 | 武田薬品工業株式会社 | 疼痛の治療 |
| US20190201454A1 (en) * | 2016-06-23 | 2019-07-04 | Mayo Foundation For Medical Education And Research | Par2 modulation to alter myelination |
| EP3596125B1 (en) * | 2017-03-16 | 2025-11-19 | MedImmune Limited | Anti-par2 antibodies and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629174A (en) * | 1993-07-26 | 1997-05-13 | Cor Therapeutics, Inc. | Recombinant C140 receptor |
| CA2211176A1 (en) * | 1995-01-25 | 1996-08-01 | Cor Therapeutics, Inc. | Recombinant c140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor |
| US20090035315A1 (en) * | 2004-06-17 | 2009-02-05 | Stephan Christgau | Method of Improving Treatments in Rheumatic and Arthritic Diseases |
-
2009
- 2009-03-16 AR ARP090100937A patent/AR070911A1/es unknown
- 2009-03-17 PE PE2009000397A patent/PE20091693A1/es not_active Application Discontinuation
- 2009-03-18 TW TW098108692A patent/TW201002345A/zh unknown
- 2009-03-18 CL CL2009000660A patent/CL2009000660A1/es unknown
- 2009-03-18 WO PCT/US2009/037504 patent/WO2009117481A1/en not_active Ceased
- 2009-03-19 UY UY0001031723A patent/UY31723A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009117481A1 (en) | 2009-09-24 |
| PE20091693A1 (es) | 2009-11-16 |
| TW201002345A (en) | 2010-01-16 |
| UY31723A (es) | 2009-11-10 |
| CL2009000660A1 (es) | 2010-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070911A1 (es) | Uso de antagonistas del receptor par2 activado con proteasa | |
| Robinson et al. | Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis | |
| Kroner et al. | Mast cells are critical regulators of bone fracture–induced inflammation and osteoclast formation and activity | |
| Yang et al. | Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial | |
| Rosero et al. | Preemptive, preventive, multimodal analgesia: what do they really mean? | |
| Bigoni et al. | Acute and late changes in intraarticular cytokine levels following anterior cruciate ligament injury | |
| Gossec et al. | European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update | |
| Adami et al. | Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial | |
| Grossman | Lupus arthritis | |
| Ong et al. | Hyaluronic acid injections in medicare knee osteoarthritis patients are associated with longer time to knee arthroplasty | |
| PE20240913A1 (es) | Anticuerpos anti-il-2r agonistas y metodos de uso | |
| Watt et al. | New drug treatments for osteoarthritis: what is on the horizon? | |
| Chen et al. | Arthrofibrosis and large joint scarring | |
| AR081434A1 (es) | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo | |
| CY1118044T1 (el) | Παρασκευασμα συνδυασμου με ανταγωνιστη και κορτικοστεροειδες | |
| Trueba Davalillo et al. | Clinical efficacy of intra-articular injections in knee osteoarthritis: a prospective randomized study comparing hyaluronic acid and betamethasone | |
| CY1123240T1 (el) | Αντισωμα αντι fgf23 και μια φαρμακευτικη συνθεση που το περιλαμβανει | |
| Tsai et al. | Isorhamnetin ameliorates inflammatory responses and articular cartilage damage in the rats of monosodium iodoacetate-induced osteoarthritis | |
| EA201070725A1 (ru) | Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона | |
| CL2011002416A1 (es) | Uso de un anticuerpo anti-il 17a y/o il-17f o fragmento que une antígeno del mismo que sirve en la preparación de un medicamento para el tratamiento de un trastorno de resistencia a insulina en un mamifero; kit. | |
| Kuswanto et al. | Repurposing drugs for the treatment of osteoarthritis | |
| Ghouri et al. | New developments in osteoarthritis pharmacological therapies | |
| Aurora et al. | T cells heal bone fractures with help from the gut microbiome | |
| Pommier et al. | NSAIDs for pain control during the peri-operative period of hip fracture surgery: a systematic review | |
| y Hernandez et al. | Viscosupplementation of the ankle: a prospective study with an average follow-up of 45.5 months |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |